Anne-Marie Masquelier joins Cegedim Strategic Data

Takes role of global medical research director

Cegedim Strategic Data (CSD), a French provider of integrated healthcare research, has appointed Dr Anne-Marie Masquelier as global medical research director of its medical research CRO activities worldwide.

Masquelier is a medical doctor MD with a specialisation in endocrinology and holds an MBA in marketing/management. She started her career as a medical practitioner before moving to the healthcare industry where she held various management positions in pharmaceutical, CRO and biotech companies. Most recently she was general manager of Genethon.

Masquelier will manage CSD’s established medical research teams in France, Germany, Italy, Spain and UK, China, Japan and the US. She will continue the expansion of this activity in all of the 39 countries where CSD is present.

You may also like

Regulatory

Power to the patient: The value of longitudinal data

Steve Bradley, Group Managing Director, Cegedim UK, outlines how data holds the key to better patient care
Finance

Cegedim Dendrite forms partnership with TAKE Solutions

Arrangement will enable Cegedim to expand its presence in India
Finance

Cegedim expands business in Switzerland

Acquires Swiss CRM and Direct Marketing businesses of IMS Health
Research & Development

Scientists develop new technique to fight antimicrobial resistance

The team of researchers from the University of Leicester have developed a new technique to sequence phage genomes from individual plaques and hopes to use it to build fully characterised libraries of bacteriophages, expanding the number of candidates available to tackle drug-resistant infections
Research & Development

Lancet Oncology Commission launches to examine future of academic cancer clinical trials amid funding and regulatory pressures

A global coalition of clinical investigators and patient representatives has launched the Lancet Oncology Commission to address the value and challenges of independent academic cancer clinical trials, amid growing concerns over regulatory complexity, limited public funding and the need for new international collaboration models
Regulatory

WHO prequalifies Novartis' antimalarial Coartem Baby for treatment of newborns and young infants

The decision allows global procurement of artemether-lumefantrine (also known as Riamet Baby in some countries) for the first time, with Novartis adding that it will make the treatment available on a largely not-for-profit basis in malaria-endemic regions
You need to be a subscriber to read this article.
Click here to find out more.
Finance

Britain's biotech potential (part II): world-class science, second-class support?

In part one, Manufacturing Chemist explored the UK’s world-class science base and early-stage investment appeal. In this second instalment, attention turns to the structural gaps that are limiting its ability to scale
Subscribe now